JNJ Johnson & Johnson
Company Analysis
Latest News
J&J Rejects Obesity Drug Market, Aiming for 2030 Cancer Leadership
CEO Joaquin Duato announced Johnson & Johnson will not develop GLP-1 drugs for the obesity market. The company will instead focus on sectors where it maintains...
Johnson & Johnson invests $1B in Florida, scaling ACUVUE production
Johnson & Johnson is investing over $1 billion to expand its vision care manufacturing and distribution operations in Jacksonville, Florida. The project will...
Johnson & Johnson Myeloma Combo Shows 89% Survival in Phase 3
Johnson & Johnson reported positive Phase 3 MonumenTAL-3 results for a combination therapy treating relapsed or refractory multiple myeloma. The study...
J&J eyes first-ever rare blood treatment approval after positive Imaavy data
Johnson & Johnson presented Phase 2/3 ENERGY study results for Imaavy (nipocalimab) at the European Hematology Association 2026 Congress. The therapy targets...
J&J Signals Faster Growth, Led by 4,500 New ICOTYDE Drug Prescribers
Johnson & Johnson executive Tom Cavanaugh provided a data-rich update at the Goldman Sachs Global Healthcare Conference on June 9. He signaled that the...
Johnson & Johnson buys Firefly Bio for $1B, targeting difficult tumors
Johnson & Johnson will acquire biotechnology firm Firefly Bio for $1 billion in cash. The deal integrates Firefly’s degrader antibody conjugate (DAC) platform...
Johnson & Johnson Reports 71% Myeloma Risk Reduction at ASCO 2026
Johnson & Johnson presented clinical trial results for its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) meeting. The Phase 3...
Johnson & Johnson Wins California Talc Trial, Defeating Ovarian Cancer Claims
A Los Angeles jury cleared Johnson & Johnson of negligence on June 5, 2026. The verdict rejected claims that the company’s talc-based powders caused fatal...
🟢 Johnson & Johnson is trading 3.1% up today on defensive rotation as broader market slides
Johnson & Johnson is trading 3.1% up at $235.13 as investors rotate into defensive healthcare stocks amid a broader market decline. • The gain comes despite...
J&J Recalls Abiomed Catheter Kits Over Serious Blood Clot Risks
The U.S. Food and Drug Administration (FDA) issued an early safety alert for specific catheter introducer kits manufactured by Johnson & Johnson’s Abiomed...
Johnson & Johnson Advances Nipocalimab, First FcRn Blocker to Succeed in Lupus
Johnson & Johnson announced that its investigational therapy, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for systemic lupus...
Johnson & Johnson Recalls Impella Heart Pumps, Linked to Patient Death
Johnson & Johnson’s Abiomed division recalled specific Impella CP with SmartAssist heart pumps. An internal review found that certain units failed to meet...
J&J’s Erleada Cuts Prostate Cancer Death Risk, Meeting Phase 3 Goals
Johnson & Johnson reported positive Phase 3 PROTEUS study results for its prostate cancer drug Erleada (apalutamide). The trial evaluated Erleada combined with...
Johnson & Johnson Lung Cancer Combo Hits 3.5-Year Survival Milestone
Johnson & Johnson announced long-term survival data for its Rybrevant and Lazcluze drug combination at the 2026 ASCO Annual Meeting. The Phase 1/1b CHRYSALIS-2...
Johnson & Johnson’s TECVAYLI Slashes Myeloma Progression Risk by 71%
Johnson & Johnson reported positive Phase 3 MajesTEC-9 trial results for its multiple myeloma treatment, TECVAYLI (teclistamab-cqyv). The study showed the drug...
J&J Secures FDA Approval for TREMFYA, First IL-23 Inhibiting Joint Damage
Johnson & Johnson received FDA approval for a supplemental Biologics License Application for TREMFYA® (guselkumab). The expanded label includes the drug's...
J&J wins China approval for nipocalimab, expanding its $6.5 billion bet
China's National Medical Products Administration approved Johnson & Johnson’s nipocalimab treatment. The drug treats generalized myasthenia gravis, a chronic...
Johnson & Johnson Reports 85.7% Response for JNJ-1900 in Phase 2 Trial
Johnson & Johnson and Nanobiotix announced positive Part 1 data from the Phase 2 CONVERGE study. The trial evaluated JNJ-1900 (NBTXR3) for stage III inoperable...
J&J’s Rybrevant Wins NICE Recommendation for NHS Lung Cancer Treatment
Johnson & Johnson announced that the UK’s National Institute for Health and Care Excellence (NICE) recommended Rybrevant (amivantamab) in combination with...
Johnson & Johnson advances IBD therapy, outperforming current treatments in Phase 2
Johnson & Johnson reported positive Phase 2b results for JNJ-4804, an investigational co-antibody therapy for ulcerative colitis (UC) and Crohn's disease...